Biotech launches personalized cancer treatment website

Share this article:
Champions Biotechnology, a company offering personalized cancer data for patients and physicians, launched a new website:

The website details Champions' personalized treatment offerings for cancer patients and their physicians, including tumorgrafts, vaccines and expert oncology panels – all catering to individual cancer patients.   

“Champions offers a more precise approach to cancer treatment, because every patient's cancer is unique,” said Doug Burkett, president of Champions Biotechnology, in a statement. “In partnership with one's physician, Champions optimizes a given treatment plan's potential for success and maximizes the patient's most precious resource: time.”

The personalized tumorgraft, for example, uses a sample of the patient's living tumor in order to test treatment options “through simultaneous evaluation of the effectiveness of numerous anti-cancer drugs,” according to the statement. A spokesperson at Champions said that the company is currently developing several of its own oncology products, but also has partnered with other biotechs including Centocor, ImClone, Concordia Pharmaceuticals and Gradalis. Personalized vaccines utilize tumorgrafts to predict a patient's immune system response to a given treatment, according to the website.

Champions' services aren't currently covered under any health insurance plan, and the patient costs for a tumorgraft, vaccine or oncology panel are not released in the public domain, according to a spokesperson.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...